SPARC receives USFDA approval for ‘ELEPSIA XR’ extended-release tablets

04 Mar 2015 Evaluate

Sun Pharma Advanced Research Company (SPARC) has received an approval from US Food and Drug Administration (USFDA) for its New Drug Application (NDA) for ELEPSIA XR (Levetiracetam extended-release tablets 1000 mg and 1500 mg).

ELEPSIA XR is indicated for adjunctive therapy in the treatment of partial onset seizures in patients 12 years of age and older with epilepsy. The product will be manufactured by Sun Pharmaceutical Industries at its Halol facility in Gujarat.

Sun Pharma Advanced Research Company (SPARC) is an international pharmaceutical company engaged in research and development of drugs and delivery systems. 

Sun Pharma Adv. Res Share Price

132.35 -1.40 (-1.05%)
30-Dec-2025 12:08 View Price Chart
Peers
Company Name CMP
Syngene Internation. 642.85
Indegene 520.00
CMS Info Systems 344.05
Sagility 52.31
Smartworks Coworking 462.50
View more..
Register Now to get our Free Newsletter & much more!

© 2025 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×